Articles liés à Risk/Benefit Analysis for the Use and Approval of Thrombolyt...
Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents: Proceedings of the Ninth Annual Symposium - Couverture rigide
Synopsis
The Symposium on New Drugs provides a forum for academic investigators, research and development personnel from the pharmaceutical industry and members of the Food and Drug Administration to discuss important clinical research issues. The Ninth Annual symposium on New Drugs addressed the problem of determining the risk versus benefit for use of three important classes of cardiovascular agents: thrombolytic, antiarrhythmic, and hypolipidemic agents. The use of thrombolytic agents has become one of the major advances in clinical intensive cardiologic care in the 1980s. While the lysis of clot(s) obstructing a major coronary artery should reverse or prevent the damage of acute myocardial ischemia and infarction, one must carefully consider the potential risks of such agents in regards to their potential benefits. The time when a thrombolytic agent should be administered to maximize benefit as well as how one defines a dose response relationship using intravenous critical care medicines were discussed as important clinical trial issues. The benefit versus risk data on currently available thrombolytic agents was reviewed and the potential roles for adjunctive agents addressed. Overall strategies regarding post- x thrombolytic care and relationships to sudden cardiac death were also detailed. The panel discussion sections provided a comprehensive view of the current thinking of the various participating groups in this symposium. Sudden cardiac death remains the number one cause of mortality in western industrialized societies.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
- ÉditeurSpringer
- Date d'édition1989
- ISBN 10 079230294X
- ISBN 13 9780792302940
- ReliureRelié
- Langueanglais
- Nombre de pages298
- ÉditeurMorganroth J., Moore E. Neil
- Coordonnées du fabricantnon disponible
Acheter neuf
Afficher cet article
EUR 227,74
EUR 9,70 expédition depuis Allemagne vers France
Destinations, frais et délaisAutres éditions populaires du même titre
Résultats de recherche pour Risk/Benefit Analysis for the Use and Approval of Thrombolyt...
Image d'archives
Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents (Developments in Cardiovascular Medicine)
Edité par
Kluwer Academic Publishers, 1989
ISBN 10 : 079230294X
ISBN 13 : 9780792302940
Ancien ou d'occasion
Couverture rigide
Vendeur : Mispah books, Redhill, SURRE, Royaume-Uni
Évaluation du vendeur 4 sur 5 étoiles
Hardcover. Etat : Very Good. Very GoodDust Jacket may NOT BE INCLUDED.CDs may be missing. book. N° de réf. du vendeur ERICA830079230294X3
Quantité disponible : 1 disponible(s)
Image fournie par le vendeur
Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents: Proceedings of the Ninth Annual Symposium on
Vendeur : moluna, Greven, Allemagne
Évaluation du vendeur 4 sur 5 étoiles
Gebunden. Etat : New. Proceedings of the Ninth Annual Symposium on New Drugs & Devices, October 27 and 28, 1988 The Symposium on New Drugs provides a forum for academic investigators, research and development personnel from the pharmaceutical industry and members of the. N° de réf. du vendeur 458436310
Quantité disponible : Plus de 20 disponibles
Image d'archives
Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents: Proceedings of the Ninth Annual Symposium on ... in Cardiovascular Medicine, 100)
Edité par
Kluwer Academic Publishers, 1989
ISBN 10 : 079230294X
ISBN 13 : 9780792302940
Neuf
Couverture rigide
Vendeur : Ria Christie Collections, Uxbridge, Royaume-Uni
Évaluation du vendeur 5 sur 5 étoiles
Etat : New. In. N° de réf. du vendeur ria9780792302940_new
Quantité disponible : Plus de 20 disponibles
Image d'archives
Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents: Proceedings of the Ninth Annual Symposium on ... in Cardiovascular Medicine, 100)
Edité par
Kluwer Academic Publishers, 1989
ISBN 10 : 079230294X
ISBN 13 : 9780792302940
Neuf
Couverture rigide
Vendeur : Lucky's Textbooks, Dallas, TX, Etats-Unis
Évaluation du vendeur 5 sur 5 étoiles
Etat : New. N° de réf. du vendeur ABLIING23Feb2416190180354
Quantité disponible : Plus de 20 disponibles
Image d'archives
Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents
Vendeur : Books Puddle, New York, NY, Etats-Unis
Évaluation du vendeur 4 sur 5 étoiles
Etat : New. pp. 316. N° de réf. du vendeur 263036719
Quantité disponible : 4 disponible(s)
Image d'archives
Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents
impression à la demandeVendeur : Majestic Books, Hounslow, Royaume-Uni
Évaluation du vendeur 5 sur 5 étoiles
Etat : New. Print on Demand pp. 316 52:B&W 6.14 x 9.21in or 234 x 156mm (Royal 8vo) Case Laminate on White w/Gloss Lam. N° de réf. du vendeur 5892592
Quantité disponible : 4 disponible(s)
Image d'archives
Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents
impression à la demandeVendeur : Biblios, Frankfurt am main, HESSE, Allemagne
Évaluation du vendeur 5 sur 5 étoiles
Etat : New. PRINT ON DEMAND pp. 316. N° de réf. du vendeur 183036709
Quantité disponible : 4 disponible(s)
Image fournie par le vendeur
Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents : Proceedings of the Ninth Annual Symposium on New Drugs & Devices, October 27 & 28, 1988
Edité par
Springer Us Jun 1989, 1989
ISBN 10 : 079230294X
ISBN 13 : 9780792302940
Neuf
Couverture rigide
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Évaluation du vendeur 5 sur 5 étoiles
Buch. Etat : Neu. Neuware - The Symposium on New Drugs provides a forum for academic investigators, research and development personnel from the pharmaceutical industry and members of the Food and Drug Administration to discuss important clinical research issues. The Ninth Annual symposium on New Drugs addressed the problem of determining the risk versus benefit for use of three important classes of cardiovascular agents: thrombolytic, antiarrhythmic, and hypolipidemic agents. The use of thrombolytic agents has become one of the major advances in clinical intensive cardiologic care in the 1980s. While the lysis of clot(s) obstructing a major coronary artery should reverse or prevent the damage of acute myocardial ischemia and infarction, one must carefully consider the potential risks of such agents in regards to their potential benefits. The time when a thrombolytic agent should be administered to maximize benefit as well as how one defines a dose response relationship using intravenous critical care medicines were discussed as important clinical trial issues. The benefit versus risk data on currently available thrombolytic agents was reviewed and the potential roles for adjunctive agents addressed. Overall strategies regarding post- x thrombolytic care and relationships to sudden cardiac death were also detailed. The panel discussion sections provided a comprehensive view of the current thinking of the various participating groups in this symposium. Sudden cardiac death remains the number one cause of mortality in western industrialized societies. N° de réf. du vendeur 9780792302940
Quantité disponible : 2 disponible(s)